Preparation of 4-[11C]methylmetaraminol, a potential PET tracer for assessment of myocardial sympathetic innervation

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 46, Issue 1, 2003, Pages 55-65

  Langer, Oliver ^a,e   Forngren, Tobias ^b   Sandell, Johan ^a   Dollé, Frédéric ^c   Långström, Bengt ^b   N̊gren, Kjell ^d   Halldin, Christer ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^d TURKU PET CENTRE   (Finland)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

4 11C methylmetaraminol; Heart; Positron emission tomography; Stille coupling; Sympathetic nervous system

Indexed keywords

AMINES; NEUROPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SYNTHESIS (CHEMICAL);

4-[11C]METHYLMETARAMINOL; AROMATIC RINGS; ARTERIAL INPUT FUNCTION; METABOLIC STABILITY; METHYL IODIDE; PALLADIUM-CATALYZED CROSS-COUPLING REACTIONS; PET TRACER; RADIOLABELLING; STILLE COUPLING; SYMPATHETIC NERVOUS SYSTEMS;

MOLECULES;

4 METHYLMETARAMINOL; METARAMINOL; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ARTICLE; CATALYSIS; DERIVATIZATION; DRUG SYNTHESIS; HEART INNERVATION; ISOTOPE LABELING; NEUROTRANSMITTER RELEASE; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RISK ASSESSMENT; SYMPATHETIC INNERVATION;

EID: 0037238624     PISSN: 03624803     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlcr.642     Document Type: Article

References (23)

1. Berti F, Shore PA. Biochem Pharmacol 1967; 16: 2091-2094.
2. Raffel DM, Wieland DM. Nucl Med Biol 2001; 28: 541-559.
3. Langer O, Halldin C. Eur J Nucl Med 2002; 29: 416-434.
4. Mislankar SG, Gildersleeve DL, Wieland DM, Massin CC, Mulholland GK, Tooronigan SA. J Med Chem 1988; 31: 362-366.
5. Wieland DM, Rosenspire K, Hutchins GD, et al. J Med Chem 1990; 33: 956-964.
6. Någren K, Halldin C, Swahn CG, Suhara T, Farde L. Nucl Med Biol 1996; 23: 221-227.
7. Langer O, Valette H, Dollé F, et al. Nucl Med Biol 2000; 27: 233-238.
8. Ermert J, Hamacher K, Coenen HH. J. Label Compd Radiopharm. 2000; 43:1345-1363.
9. Langer O, Dollé F, Valette H, et al. Bioorg Med Chem 2001; 9: 677-694.
10. Rosenspire KC, Haka MS, Van Dort ME, et al. J Nucl Med 1990; 31: 1328-1334.
11. Schwaiger M, Kalff V, Rosenspire K, et al. Circulation 1990; 82: 457-464.
12. Fuller RW, Snoddy HD, Perry KW, Bernstein JR, Murphy PJ. Biochem Pharmacol 1981; 30: 2831-2836.
13. Maitre L, Staehelin M. Nature 1965; 206: 723-724.
14. Rosenspire KC, Gildersleeve DL, Massin CC, Mislankar SG, Wieland DM. Nucl Med Biol 1989; 16: 735-739.
15. Bhatt MV. Synthesis 1983; 249-282.
16. Suzuki M, Doi H, Björkman M, et al. Chem Eur J 1997; 3: 2039-2042.
17. Yu M, Någren K, Halldin C, Swahn CG, Helfenbein J, Guilloteau D. J Label Compd Radiopharm 1999; 42: S469-S471.
18. Björkman M, Doi H, Resul B, et al. J Label Compd Radiopharm 2000; 43: 1327-1334.
19. Tarkiainen J, Vercouille J, Emond P, et al. J Label Compd Radiopharm 2001; 44: 1013-1023.
20. Sandell J, Halldin C, Sovago J, et al. Nucl Med Biol 2002; 29: 651-656.
21. Larsen P, Ulin J, Dahlstrøm K, Jensen M. Appl Radiat Isot 1997; 48: 153-157.
22. Långström B, Antoni G, Gullberg P, et al. J Nucl Med 1987; 28: 1037-1040.
23. Bjurling P, Reineck R, Westerberg G, et al. Proceedings from VIth Workshop on Targetry and Target Chemistry, Vancouver, BC, Canada, August 1995.